{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 42,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like structure to compare drug generations against clinical outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/14",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a307b8a4-1691-47c0-8a3a-f26a5cc7c488",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.15,
        "y": 0.83
      },
      "kind": "legend",
      "text": "Observed in clinical investigation",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8544b94e-1047-42bb-b631-79d89fec201a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Comparison matrix of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib vs NVL-655 across ALK activity, mutant activity, CNS activity, and TRK sparing.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acd56ce2-06c5-48e2-94fb-a419d3b306ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "NVL-655: A Rationally Designed ALK-selective, TRK-sparing Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5cbc097-76f2-4434-bef6-95cd4ce27bff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "764faede-02cc-47eb-ab62-2247763b691c",
      "evidence": "table/data: Comparison matrix of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib vs NVL-655 across ALK activity, mutant activity, CNS activity, and TRK sparing.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "7bc906df-1b10-4e84-8922-073ff1ff0d0b",
      "evidence": "Matrix comparing drug generations against clinical outcomes",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}